With an already overwhelming respiratory virus season with RSV and influenza, the hope is to prevent COVID-19 with these vaccines available to younger pediatric populations.
Today, the FDA announced it had amended the emergency use authorizations (EUAs) of the updated (bivalent) Moderna and Pfizer-BioNTech COVID-19 vaccines to include use in children down to 6 months of age.
“More children now have the opportunity to update their protection against COVID-19 with a bivalent COVID-19 vaccine, and we encourage parents and caregivers of those eligible to consider doing so – especially as we head into the holidays and winter months where more time will be spent indoors,” said FDA Commissioner Robert M. Califf, MD, said in a statement.
According to the FDA, parents and caregivers should know the following about the vaccines:
Children 6 months through 5 years of age who received the original (monovalent) Moderna COVID-19 Vaccine are now eligible to receive a single booster of the updated (bivalent) Moderna COVID-19 Vaccine two months after completing a primary series with the monovalent Moderna COVID-19 Vaccine.
The respiratory virus season has been extremely challenging in recent months and concerns of the tripledemic (RSV, influenza, and COVID-19) have been front of mind for clinicians, parents and public health officials. There have been reports of RSV overwhelming pediatric units in hospitals, and influenza incidence rates increasing dramatically.
Without the benefit of an RSV vaccine available yet, vaccine uptake for both influenza and COVID-19 remains vital to
“Vaccines remain the best defense against the most devastating consequences of disease caused by the currently circulating omicron variant, such as hospitalization and death. Based on available data, the updated, bivalent vaccines are expected to provide increased protection against COVID-19,” Peter Marks, MD, PhD, director of the FDA’s Center for Biologics Evaluation and Research, said in the same statement.